Updated:
Jasper Therapeutics
Jasper Therapeutics, led by CEO Ronald Martell, advances briquilimab, a c-Kit antibody for safer stem-cell transplants.
Jasper Therapeutics
Jasper Therapeutics was founded in 2019 to develop targeted conditioning agents that clear space for hematopoietic stem-cell transplants — an approach designed to make these procedures safer and more broadly applicable. The company traces its platform to research at Stanford University and launched as a spinout of Amgen's former inflammation division. Ronald Martell, previously CEO of Achieve Life Sciences and an executive at Genentech and Roche, joined as president and CEO at inception. The firm concentrates exclusively on the conditioning phase of stem-cell transplant, specifically with its lead antibody briquilimab, which targets c-Kit (CD117) to deplete diseased stem cells. This differs from the bifurcated strategies typical of early-stage immuno-oncology companies; Jasper is betting that a single mechanism can unlock curative gene therapies, immune reset in autoimmune disease, and improved outcomes in bone marrow transplant. The company has disclosed clinical-stage programs in chronic spontaneous urticaria and lower-risk myelodysplastic syndromes, with data readouts anticipated in the 2025–2026 window. It maintains a lean, in-house development engine while relying on academic partnerships and contract manufacturing, most notably with Stanford and partners in the CSTR and BEACON trials. Jasper became a public company via a reverse merger in 2022 — absorbing the shell of a dried-up SPAC — and then completed a $103 million underwritten public offering in March 2023. The executive team includes CMO Edwin Tucker, who previously held senior clinical roles at Amgen and holds an MD from Cambridge, and COO/CFO Jeet Mahal, a veteran of Genentech finance. A notable operational milestone came in January 2024 when the firm centralized manufacturing for briquilimab under a long-term supply arrangement with a European CDMO, which resolved a prior reliance on fragmented academic batch production (per SEC filings, 2024). The company operates as a classic biotechnology platform with a single New York Stock Exchange listing (ticker: JSPR), no philanthropic carve-out, and no parallel venture-arm structure. What separates Jasper from the dozens of other pre-revenue clinical-stage biotechs is its structural concentration on the conditioning niche. It does not own a gene therapy, a cell therapy, or a diagnostic. Instead, briquilimab is positioned as the overlaying conditioner for other companies' curative therapies — a role that makes licensing partnerships, rather than pipeline breadth, the firm's commercial pivot.
General information
Firm type
Asset Manager
Year founded
2019
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Redwood City
Corporate office
Redwood City, CA, United States
Principals
Ronald Martell
President and Chief Executive Officer
Edwin Tucker
Chief Medical Officer
Jeet Mahal
Chief Operating Officer and Chief Financial Officer
Sector focus
Frequently asked questions
What is Jasper Therapeutics's lead clinical asset and how does it work?
The firm's lead asset is briquilimab, a monoclonal antibody that targets c-Kit (CD117) found on hematopoietic stem cells. By blocking this receptor, briquilimab depletes diseased stem cells from the bone marrow, creating an empty niche for donor or gene-corrected cells. Jasper is pursuing this mechanism across multiple indications, including chronic spontaneous urticaria and myelodysplastic syndromes, under a single-platform clinical development model.
Who is in charge of clinical development and what is his background?
Edwin Tucker, the chief medical officer, leads clinical development. Tucker holds an MD from the University of Cambridge and has previously led a Phase 3 oncology program at Amgen. His experience spans immuno-oncology and bone-modifying agents, which are directly relevant to the hematopoietic stem-cell platform Jasper is building.
How is Jasper Therapeutics financed, and when did it become a public company?
Jasper became a public company in 2022 via a reverse merger with a SPAC vehicle, and subsequently raised approximately $103 million in a March 2023 underwritten public offering. As a pre-revenue, clinical-stage company, it has historically funded operations through public equity raises rather than venture capital, which gives it a different capital-structure profile from privately backed biotechs.
What makes Jasper's strategy different from other stem-cell therapy companies?
Jasper does not develop cell or gene therapies. It focuses exclusively on conditioning — preparing the patient's bone marrow to accept a transplant — making its asset a potential pairing partner for other curative therapies rather than a competitor. This places the firm at the front end of the hematopoietic stem-cell transplant workflow, where it can collaborate with gene-therapy developers without the overhead of owning a cell-manufacturing capability.
What are the known upcoming catalysts for Jasper Therapeutics?
The primary catalysts are data readouts from the ongoing BEACON trial in chronic spontaneous urticaria and the CSTR study in lower-risk MDS, both expected in the 2025–2026 timeframe. These programs are designed to show whether briquilimab can safely and effectively deplete aberrant mast cells or malignant stem cells in distinct disease settings, which would be a major de-risking event for the platform.
Where is Jasper Therapeutics located and does it have any other facilities?
Jasper is headquartered in Redwood City, California. It does not maintain additional physical offices, but manages a distributed clinical-trial network in the U.S. and Europe. In January 2024, the firm consolidated its manufacturing with a single European contract development and manufacturing organization, per SEC filings, centralizing the supply chain that was previously run through academic facilities.
Does Jasper Therapeutics have any philanthropic or non-commercial structures?
No. Jasper operates as a standard for-profit biotechnology public company listed on the New York Stock Exchange under the ticker JSPR. It has not established any separate patient-access foundations or charitable vehicles, and its clinical development is funded through the public markets rather than through grant-based or nonprofit mechanisms.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: